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Summary 
Background and Objectives  
Anagrelide represents a treatment option for essential thrombocythemia patients. It lowers 
platelet counts through inhibition of megakaryocyte maturation and polyploidization, although 
the basis for this effect remains unclear. Based on its rapid onset of action, we assessed 
whether, besides blocking megakaryopoiesis, anagrelide represses proplatelet formation 
(PPF) and aimed to clarify the underlying mechanisms. 
Methods and Results 
Exposure of cord blood-derived megakaryocytes to anagrelide during late stages of culture 
led to a dose- and time-dependent inhibition in PPF and reduced proplatelet complexity, 
which were independent of anagrelide-induced effect on megakaryocyte maturation. 
Whereas anagrelide was shown to phosphorylate cAMP-substrate VASP, two 
pharmacologic inhibitors of the cAMP pathway were completely unable to revert anagrelide-
induced repression in megakaryopoiesis and PPF, suggesting these effects are unrelated to 
its ability to inhibit phosphodiesterase (PDE) 3. The reduction in thrombopoiesis was not the 
result of downregulation of transcription factors which coordinate PPF, while the myosin 
pathway was identified as a candidate target, as anagrelide was shown to phosphorylate 
myosin light chain and the PPF phenotype was partially rescued after inhibition of myosin 
activity with blebbistatin. 
Conclusions 
The platelet-lowering effect of anagrelide results from impaired megakaryocyte maturation 
and reduced PPF, both of which are deregulated in essential thrombocythemia. These 
effects seem unrelated to PDE3 inhibition, which is responsible for anagrelide´s 
cardiovascular side effects and antiplatelet activity. Further work on this field may lead to the 
potential development of drugs to treat thrombocytosis in myeloproliferative disorders with 
improved pharmacologic profile.  
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Introduction 
Anagrelide is a platelet-lowering agent which represents a treatment option for patients with 
essential thrombocythemia [1,2].  It has a selective effect on megakaryocytes, while sparing 
the myeloid and erythroid lineages, rendering particularly useful for treatment of patients with 
isolated thrombocytosis. Anagrelide was originally developed as an antiplatelet agent [3], 
while the thrombocytopenic effect of this drug was discovered during preclinical trials [4]. 
Mazur et al demonstrated that anagrelide exerts its effects by influencing the postmitotic 
phase of megakaryocyte development, decreasing megakaryocyte ploidy and size [5], 
whereas it reduces megakaryocyte colony growth only at 10-fold higher in vitro 
concentrations, several-fold higher than those achieved in vivo, suggesting it has no relevant 
effect on megakaryocyte progenitors at therapeutic doses. Accordingly, although one study 
described reduced numbers of megakaryocytes by flow cytometric analysis of bone marrow 
samples from anagrelide-treated patients [6], this finding was not supported by bone marrow 
histological evaluation [7]. During normal megakaryocyte development, after reaching 
maturation, megakaryocytes form long, branched cytoplasmic extensions named 
proplatelets, which protrude into the bone marrow sinusoidal lumen where platelets are 
released from proplatelet tips, a process that is completed within a few hours [8]. Based on 
anagrelide´s rapid onset of action, we hypothesized that besides blocking megakaryocyte 
polyploidization and maturation, anagrelide inhibits later stages of platelet production, 
characterized by proplatelet formation (PPF), which would result in faster changes in platelet 
counts. 
Although anagrelide has been used in clinical practice since the late 1980´s, the molecular 
mechanisms underlying its platelet-lowering activity remain still unclear. Results from initial 
studies using hematopoietic cell lines proposed that anagrelide interfered with signaling from 
the Mpl receptor [9], although subsequent data in primary human hematopoietic cells failed 
to support these observations [10]. More recently, megakaryocytes exposed to anagrelide at 
concentrations which inhibit megakaryocyte maturation were shown to express reduced 
levels of key megakaryocyte transcription factors, including GATA-1, FLI-1 and NF-E2 [10]. 
Whether anagrelide suppresses megakaryopoiesis by exerting a direct effect on 
megakaryocyte transcriptional axis or, alternatively, whether this finding reflects the 
presence of more immature megakaryocytes expressing lower levels of these transcriptional 
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Anagrelide inhibits cyclic adenosine monophosphate (cAMP) phosphodiesterase (PDE) 3 
[11]. Stimulation of cAMP signaling by pharmacologic agents has been reported to block 
megakaryocyte differentiation and maturation [12]. Based on the fact that anagrelide is a 
PDE3 inhibitor, it is plausible to consider that its effects on the megakaryocyte are mediated 
through elevation of cAMP levels. Recently, megakaryocytic inhibition by cAMP was shown 
to be mediated by protein kinase A (PKA)–dependent downregulation of transcription factor 
E2A and its target CDKN1A (p21) and that, similarly, anagrelide represses this regulatory 
E2A/p21 loop, suggesting the potential involvement of cAMP in anagrelide´s mechanism of 
action [13]. On the other hand, the fact that other commercially available PDE3 inhibitors 
have no effect on in vitro megakaryocyte maturation argues against the possible 
participation of this second messenger in anagrelide-induced platelet reduction [14]. In 
addition, certain differences exist between anagrelide´s platelet antiaggregating activity, 
which is known to rely upon cAMP elevation, and its platelet lowering effect. First, inhibition 
of platelet function is achieved at higher anagrelide concentrations than those required for 
megakaryocyte inhibition [15]. Also, whereas its antiaggregating activity is seen in vitro and 
ex vivo in humans and several other species, the platelet-lowering effect is exerted only in 
humans, suggesting that different mechanisms mediate both actions [3,4]. However, as yet, 
the role of anagrelide´s PDE3 inhibitory activity in its platelet-lowering effect has not been 
directly explored.  
 
In this study, we show that besides blocking megakaryopoiesis, anagrelide exerts a direct 
inhibitory effect on thrombopoiesis and that both actions are, at least partly, independent of 
PDE3 inhibition. In addition, we explore other molecular mechanisms which may underlie the 
effects of this compound on platelet biogenesis and identify the myosin pathway as a 
potential target. 
 
Materials and Methods 
Megakaryocyte culture and proplatelet formation 
After informed consent, CD34+ cells were purified by immunomagnetic separation (Miltenyi 
Biotech Ltd., Bisley, Surrey, UK) from cord blood, which was collected following normal 
deliveries, and from primary peripheral blood CD34+ cells obtained from a patient with 
essential thrombocythemia. Cells were cultured in StemSpan medium (Stem Cell 
Technologies, Vancouver, BC, Canada) supplemented with 10ηg/mL thrombopoietin 
(Miltenyi Biotec Ltd.) and 10ηg/mL interleukin 6 (Miltenyi Biotec Ltd.). To assess 
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conjugated CD61 and CD42b-phycoerythrin (BD Biosciences, San José, CA, USA) followed 
by flow cytometry. To evaluate PPF, 104 cells were seeded on 96-well plates at day 13 of 
culture, PPF was monitored daily by phase-contrast microscopy (Axiovert 25, Carl Zeiss 
GmbH, Göttingen, Germany) and peak PPF was recorded, as described [16].  
 
Drug treatment  
Anagrelide hydrochloride (NewChem Technologies Limited, Durham, UK) was prepared in 
dimethylsulfoxide (DMSO) (Sigma-Aldrich). Control cultures were incubated with an 
equivalent amount of DMSO. Two different treatment schedules were used. In schedule A, 
which was used to assess the effect of anagrelide or dibutyryl (db)-cAMP (Sigma-Aldrich, St 
Louis, MO, USA) in megakaryopoiesis, cells were incubated with the selected compounds 
since day 1 of culture and exposed to the drugs all along the culture period until day 12, at 
which point analysis was carried out. In schedule B, which was applied to study PPF, cells 
were grown in the absence of drugs and these were added at day 13 of culture, including 
anagrelide, db-cAMP or prostaglandin (PG) E1 (Sigma-Aldrich). In selected experiments, 
cells were preincubated with the PKA inhibitor, PKI (14-22) amide (myristoylated) (Enzo Life 
Sciences, Plymouth Meeting, PA, USA), the competitive inhibitor Rp-cAMPS (Sigma-
Aldrich), or the selective inhibitor of myosin II ATPase activity, blebbistatin (Sigma-Aldrich) 
during 30 min. prior to anagrelide or db-cAMP addition, as indicated for each experiment.  
 
Immunofluorescence analysis of megakaryocytes and proplatelets 
Cells were cytocentrifuged, fixed with 3% paraformaldehyde, permeabilized with 0.2% Triton 
X-100, stained with CD61-FITC and Hoechst 33258 (Sigma-Aldrich) and analyzed under an 
epifluorescent microscope (Carl Zeiss GmbH). Images were acquired using a digital camera 
(Canon Power Shot G6, Tokyo, Japan). Megakaryocytes were classified into maturation 
stages according to standard criteria [17] and megakaryocyte diameter was determined 
using the VideoTesT-Master Morphology image analysis software (St. Petersburg, USSR). 
To assess PPF on fibrinogen and proplatelet complexity, 1 x 105 megakaryocytes were 
treated with anagrelide or vehicle at day 13 of culture and seeded on fibrinogen-coated 
coverslips in 24-well plates, as described [16]. After 48 hours, cells were stained as detailed 
before. Then, PPF was assessed and the number of swellings and platelet-like structures 
(tips) on each proplatelet-bearing megakaryocyte were counted. Proplatelet length and 
maximum shaft thickness were analyzed with the same software used for image analysis. At 
least 40 megakaryocytes producing proplatelets were analyzed for each sample. To assess 
adhesion and spreading on collagen, day 13 megakaryocytes were treated or not with 
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collagen (kindly provided by Prof. Tura and Dr. Gruppi, University of Pavia, Italy), as 
described [18]. After 16 hours, non-adherent cells were removed and, after gentle washing, 
cells were fixed, stained with FITC-labeled phalloidin (Sigma-Aldrich) to assess percentage 
of cells showing spreading or with CD61 antibody to count the number of adherent 
megakaryocytes.  
 
Megakaryocyte gene expression analysis  
Cord blood-derived CD34+ cells were cultured as described before and allophycocyanin 
(APC)-conjugated CD41+ cells were purified on day 9 by fluorescence-activated cell sorting 
(FACSAria II, BD Biosciences), cell purity of the sorted population was 98%. At day 13, 
megakaryocytes were incubated with 50ηM anagrelide during 48 hours. Then, RNA was 
isolated from non-treated and treated cells using RNeasy Micro kit (Qiagen, Hilden, 
Germany). After reverse transcription, expression levels of target genes were measured in 
triplicate by real-time PCR relative to GAPDH using SYBR® Green (Life Technologies, NY, 
USA) in an iCycler (Bio Rad Life Science, CA, USA), primer sequences are listed in Table 
S1.  
 
Western blot analysis 
Cells were stimulated with anagrelide, db-cAMP or vehicle at concentrations detailed for 
each experiment and 1 x 106 cells were lysed with RIPA buffer (50mM Tris-HCl, 150mM 
NaCl, 1% NP-40, 0.5% sodium deoxycholate, 0.1% SDS) and subjected to SDS-PAGE. In 
selected experiments, 2 x 106 cells were treated or not with anagrelide, allowed to adhere to 
25μg/mL type I collagen-coated 6 well-plates during 16 hours and lysed after removal of 
non-adherent cells. For immunoblotting, membranes were probed with rabbit polyclonal 
phospho (p)-vasodilator-stimulated phosphoprotein (VASP) (Ser157) antibody (Cell 
Signaling Technology, Danvers, MA) or mouse phospho-myosin light chain 2 (MLC2) 
(Ser19) monoclonal antibody (Cell Signaling Technology), followed by the corresponding 
horseradish peroxidase-conjugated secondary antibodies. Protein loading was assessed 




Data are presented as mean ± standard deviation (SD) or standard error of the mean (SEM), 
as indicated. Comparison between groups was performed using paired t-test or repeated 
measures ANOVA followed by Tukey´s multiple comparison test. P values < 0.05 were 
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Results 
Anagrelide-induced inhibition in proplatelet formation  
First, we confirmed in our culture system that, as reported, exposure of cord blood-derived 
CD34+ cells to 500ηM anagrelide since the beginning and all along the culture period (day 1 
to day 12) inhibits megakaryocyte maturation, as assessed by percentage of double positive 
CD61+CD42b+ cells and stratification in maturation stages according to size and nuclear 
lobulation, without affecting megakaryocyte colony growth (data not shown). Then, to assess 
the effect of anagrelide on PPF, cord blood-derived megakaryocytes were grown for 12 days 
and, at day 13 of culture, cells were exposed to anagrelide. A dose-dependent inhibition in 
PPF was found (Fig.1A). However, although no cell toxicity was observed when cells were 
exposed to up to 1μM anagrelide during earlier stages of culture, exposure of day 13 mature 
megakaryocytes to >250ηM led to increased cell death, as determined by Trypan blue 
exclusion (data not shown). Therefore, to evaluate PPF, subsequent experiments were 
performed using lower dosis. A significant reduction in proplatelet counts was found after 
incubation with 50ηM anagrelide, 1.47±0.2 vs. 4.80±0.5%, p=0.0002, paired t-test 
(Fig.1B,C). In addition to decreased PPF observed in cells in suspension, reduced PPF was 
reproduced when tested after megakaryocyte adhesion to fibrinogen, 1.39±0.10 vs. 
3.27±0.19, p< 0.0001, paired t-test, n=5.This treatment schedule did not affect 
megakaryocyte viability (99.4±5.7% of control untreated cells), ploidy (Fig. S1A) and 
maturation, as assessed by %CD61+CD42b+ cells (70.45±6.2 for 50ηM anagrelide-treated 
cultures and 73.82.11±6.7% for untreated cells, P > 0.05) and analysis of megakaryocyte 
maturation stages by immunofluorescence (Fig. S1B), indicating a direct effect of anagrelide 
in thrombopoiesis. To assess the time-course effect of anagrelide on PPF, megakaryocytes 
were incubated with 50ηM anagrelide during increasing time periods. As shown (Fig 1D), the 
degree of PPF inhibition increased over time, reaching 52.33±9.9%, 27.16±1.5%, 19.3±4.2 
and 15.63±4.7% of control levels at 24, 48, 72 and 96-hour incubation period, respectively.  
 
Effect of anagrelide on proplatelet complexity from normal cord blood-derived and 
primary essential thrombocythemia megakaryocytes 
We then evaluated whether, besides reducing PP counts, anagrelide influences PP 
architecture. To this end, day 13 megakaryocytes were incubated with 50ηM anagrelide and 
seeded on fibrinogen-coated matrices followed by immunofluorescence analysis. Anagrelide 
induced an overall reduction in proplatelet complexity, as shown by the decrease in the 
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number of tips and decreased proplatelet length (Fig. 2A,B). In addition, proplatelet shafts 
were wider in anagrelide-treated megakaryocytes (Fig. 2A,B). To assess if the effect of 
anagrelide on PPF could be relevant in the clinical setting, primary CD34+ peripheral blood 
cells from an untreated patient with essential thrombocythemia were cultured in the same 
conditions as cord-blood cells. Percentage of double positive CD61+CD42b+ cells after 12 
days of culture was 92.5%. After exposure of mature megakaryocytes to 50ηM anagrelide 
during 48hs, proplatelets from essential thrombocythemia megakaryocytes incubated with 
vehicle showed extensive ramification and numerous proplatelet tips, as previously reported 
[19], while a profound inhibition in PPF was found after incubation with 50ηM anagrelide, 
reaching 7.96±0.6% of proplatelet counts obtained in untreated cells. In addition, the few 
proplatelets formed in the presence of anagrelide were poorly developed (Fig. 2C). 
 
Effect of anagrelide on megakaryocyte VASP phosphorylation 
To assess whether anagrelide´s effects on the megakaryocyte are mediated by its ability to 
inhibit PDE3, we first studied whether this drug stimulates cAMP signaling in 
megakaryocytes by measuring the phosphorylation status of cAMP-substrate VASP on 
Ser157, which is the major PKA-dependent phosphorylation site. Results showed that 
treatment of cells with 500ηM anagrelide during the whole culture period (day 1 to day 12), 
which was the schedule used to inhibit megakaryopoiesis, was capable of inducing VASP 
phosphorylation, while 48-hour incubation of mature day 13 MKs with 50ηM anagrelide, the 
approach used to inhibit thrombopoiesis (schedule B), did not modify pVASP levels (Fig.3A), 
which suggests that anagrelide-induced inhibition in PPF is unrelated to its PDE3 inhibitory 
activity. We then compared the effect of addition of increasing concentrations of cAMP 
analog dibutyryl (db)-cAMP since the onset and all along the culture period respect to those 
elicited by 500ηM anagrelide in schedule A on VASP phosphorylation (shown in Fig 3B) and 
megakaryocyte maturation. The latter was assessed by measuring CD42b expression, which 
was 38, 66, 41 and 32% of control levels for 500ηM anagrelide and 10µM, 20 µM, 35 µM db-
cAMP, respectively.  The finding that for similar degree of inhibition in megakaryocyte 
maturation, 20μM db-cAMP induced higher levels of pVASP as compared to anagrelide (Fig. 
3B) suggests that anagrelide´s effect on megakaryocyte maturation is, at least partly, 
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Role of cAMP blockade in anagrelide-induced inhibition in megakaryothrombopoiesis  
We next assessed whether blockade of the cAMP pathway by two different pharmacologic 
inhibitors, the PKA inhibitor, PKI, and the competitive inhibitor Rp-cAMP, interfered with 
anagrelide´s effect on megakaryopoiesis and thrombopoiesis. Neither 100ηM PKI nor 
500µM Rp-cAMP were able to revert anagrelide-induced inhibition in megakaryocyte 
maturation (Fig. 4A), while 100ηM PKI was able to partially revert the effect of 20μM db-
cAMP (data not shown), in accordance with recent data showing that cAMP exerts its 
inhibitory effect in the megakaryocyte lineage through a PKA-dependent mechanism [13]. 
Similar results were obtained when the addition of 500ηM anagrelide was delayed until day 
4 of culture and also when lower 250ηM anagrelide concentrations or higher PKI doses, up 
to 1 μM, were used (data not shown). As for megakaryocyte maturation, neither 100ηM PKI 
nor 500µM Rp-cAMP were able to counteract the inhibitory effect of anagrelide in PPF (Fig. 
4B). Interestingly, we found that, in addition to its inhibitory effect in megakaryopoiesis, 
incubation of mature (day 13) megakaryocytes with 20μM db-cAMP reduced PPF, 1.88±0.6 
vs. 4.91±0.7, n=7 independent experiments, P < 0.01, paired t-test. Similar effect was 
obtained by treatment of cultures with 1μM cAMP-elevating agent PGE1, 1.29±0.18 vs. 
3.54±0.7, n=4 independent experiments, p < 0.05, paired t-test. Addition of 100ηM PKI 
prevented the inhibitory effect of 20μM db-cAMP on this process (Fig 4C), showing that, as 
reported for megakaryopoiesis, cAMP inhibitory effect in PPF is also mediated by the PKA 
pathway. Altogether, these data indicate that, despite inducing mild activation of cAMP-
mediated pathways when used at 500ηM, anagrelide´s effects on the megakaryocyte seem 
to be, at least partly, independent of cAMP signaling. In contrast to its effects on the 
megakaryocyte, PKA blockade with PKI was able to partially revert anagrelide-mediated 
inhibition in platelet aggregation (Fig. S2), which is known to rely on its PDE3 inhibitory 
activity [15].  
 
Gene expression pattern of molecules involved in proplatelet formation in anagrelide-
treated megakaryocytes 
To gain insight into the mechanisms underlying anagrelide-induced inhibition in PPF, we 
assessed whether short-term exposure of mature day 13 megakaryocytes with anagrelide at 
concentrations shown to inhibit PPF (e.g. 50ηM) leads to dysregulation of transcription 
factors involved in thrombopoiesis. Levels of transcription factor NF-E2 and its targets, 
RAB27B and β1-tubulin, as well as that of RUNX1 and the transcriptional complex 
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myosin light chain 2 (MLC2) were not reduced by anagrelide treatment (Fig. 5), indicating 
that anagrelide-induced inhibition in PPF is not due to decreased expression of these key 
molecular regulators of thrombopoiesis. In addition, no change in gene expression of the 
megakaryocytic regulator E2A, which is modulated by cAMP signaling, was found under 
these conditions (data not shown), whereas 500ηM anagrelide has been reported to repress 
the E2A/p21 loop when added since the beginning of culture [13]. 
 
Role of the myosin pathway in anagrelide-induced effects on the megakaryocyte 
Recent data highlight the key negative role of the Rho/Rho kinase/MLC2/myosin IIA cascade 
in proplatelet formation [20,21]. To evaluate the potential involvement of this pathway in 
anagrelide´s effect on thrombopoiesis, we studied the phosphorylation status of MLC2 after 
treatment of megakaryocytes with 50ηM anagrelide. As shown (Fig. 6A), anagrelide induced 
MLC2 phosphorylation on mature megakaryocytes, while, as expected [22], 20µM db-cAMP 
did not. Then, we evaluated whether the effect of anagrelide on thrombopoiesis could be 
reverted after blocking myosin II activity with blebbistatin. When mature day 13 
megakaryocytes were incubated with increasing concentrations of blebbistatin prior to 50ηM 
anagrelide addition, proplatelet counts rose up to control levels but did not reach levels 
achieved by blebbistatin alone (Fig. 6B), indicating that myosin inhibition can partially 
counteract the repressive effect of anagrelide in thrombopoiesis. Since MLC phosphorylation 
lies downstream of α2β1 collagen receptor engagement [23], we explored whether 
anagrelide modifies megakaryocyte behavior upon interaction with type I collagen.  
Incubation with 50ηM anagrelide did not influence megakaryocyte adherence and spreading 
on type I collagen, 100.7 ± 5.7 and 93.9 ± 15.3% of control, respectively, n=3, whereas 
adhesion to this extracellular matrix protein triggered similar levels of MLC phosphorylation 
in both control and anagrelide-treated cells (Fig. S3). 
 
Considering that downregulation of non-muscle myosin IIB during normal megakaryocyte 
development is necessary for cells to undergo the mitosis-endomitosis switch favouring 
polyploidization [24], we assessed whether enhanced myosin activity could also be 
responsible for anagrelide-induced inhibition in megakaryopoiesis. To this end, blebbistatin 
was added at day 7 of culture followed by 500ηM anagrelide during 72 hours, as longer 
incubation periods with blebbistatin were associated with cell toxicity. Megakaryocyte 
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expression but had no significant effect on nuclear lobulation and size, preventing us from 
assessing the ability of blebbistatin to counteract the effect of anagrelide on these latter two 
parameters. Although blebbistatin was able to partially increase megakaryocyte lobulation 
and size in anagrelide-treated cells,  as determined by assessment of megakaryocyte 
maturation stages and megakaryocyte diameter after immunofluorescence analysis (Fig. 7 




Platelet biogenesis results from a complex process which involves differentiation of the 
hematopoietic stem cell to the megakaryocytic lineage, followed by megakaryocyte 
polyploidization and maturation leading to PPF and platelet release into the bloodstream. 
Fine tuning of platelet production occurs at multiple steps, including megakaryopoiesis and 
thrombopoiesis. Whereas the mechanisms governing megakaryopoiesis are well 
characterized, factors that guide PPF are beginning to be unraveled and comprise both 
intrinsic megakaryocytic signals and microenvironmental clues [25]. This study shows that 
besides its known effect in megakaryocyte maturation and polyploidization, anagrelide exerts 
a direct inhibitory effect on thrombopoiesis. This effect was evident at anagrelide in vitro 
concentrations which do not affect megakaryopoiesis (data not shown) and within those 
achieved in vivo, suggesting it may be relevant at regular therapeutic doses in the clinical 
setting. The inhibition in thrombopoiesis, which represents the final stages of platelet 
production and is accomplished within few hours, may contribute to the rapid onset of action 
of anagrelide. While megakaryocyte lineage expansion with increased numbers of mature 
megakaryocytes represent key features leading to thrombocytosis in essential 
thrombocythemia, more recently, enhanced PPF and increased proplatelet complexity have 
been shown to represent additional mechanisms leading to high platelet counts [19]. 
Therefore, anagrelide´s platelet lowering effect occurs at two different levels, involving 
megakaryopoiesis and thrombopoiesis, both of which are deregulated in this 
myeloproliferative disorder. We show that in vitro anagrelide inhibits proplatelet formation 
also in primary megakaryocytes derived from a patient with essential thrombocythemia, 













This article is protected by copyright. All rights reserved. 
Phosphodiesterase inhibition accounts for anagrelide-induced block in platelet aggregation 
and for its positive inotropic and vasodilatory properties, which lead to cardiovascular 
toxicity. Elevation of intracellular cAMP levels impairs megakaryocytic differentiation [12] and 
more recently, cyclic nucleotides have been shown to exert opposite effects on platelet 
release by mature murine megakaryocytes, with cAMP playing an inhibitory role and cGMP 
stimulating this event [26]. In this study, we confirm the repressive effect of cAMP on late 
stages of platelet production showing that, besides inhibiting megakaryopoiesis, cAMP 
interferes with PPF in a PKA-dependent manner, resembling anagrelide´s dual action on the 
megakaryocyte lineage. Considering that anagrelide has been shown to raise cAMP levels in 
platelets [27], we assessed whether it is able to stimulate cAMP-dependent pathways in 
megakaryocytes.  We show that, whereas anagrelide phosphorylates VASP when added at 
doses used to inhibit megakaryopoiesis (500ηM), no changes in pVASP levels are found 
when megakaryocytes are incubated with this compound at lower doses (50ηM), which we 
show here to block thrombopoiesis. When compared with 20μM cAMP analog db-cAMP, for 
similar potency regarding their activity on megakaryopoiesis, anagrelide induced lower levels 
of pVASP, suggesting the involvement of cAMP-independent pathways in this effect. These 
findings together with the fact that blockade of the cAMP pathway is not able to revert 
anagrelide-induced inhibition in megakaryopoiesis and PPF argue against relevant 
participation of cAMP in this drug´s platelet-lowering activity. Thus, the mechanisms 
underlying anagrelide´s therapeutic effect, e.g. platelet reduction, seem to differ from those 
responsible for cardiovascular toxicity, which represents one of the most common adverse 
effects during anagrelide therapy, the latter being related and the former, unrelated, to PDE3 
inhibition. Should it be possible to dissociate these actions, these findings could be 
translated into the potential development of novel platelet-lowering agents with improved 
pharmacologic profile. The recent development of rafigrelide, which is a chemical analog of 
anagrelide with reduced potency against PDE3, may help reduce side effects, while 
preserving its platelet-lowering activity [28].  
 
Based on the finding that cAMP-independent pathways are involved in anagrelide-induced 
effects on the megakaryocytic lineage, we searched for other potential mechanisms which 
could underlie its platelet-lowering activity. First, we explored whether the block in 
thrombopoiesis could be explained by interference with transcription factors acting on late 
megakaryocyte stages. When mature megakaryocytes were treated with anagrelide using 
the schedule shown here to inhibit thrombopoiesis (e.g. 48-hour exposure to 50ηM 
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unchanged, including NF-E2, RUNX1 and MAL/ SRF, as well as that of their molecular 
targets involved in this event, such as RAB27B GTPase, β1-tubulin and MLC2, indicating 
that the direct effect of anagrelide on thrombopoiesis is not a result of disturbance of the 
transcriptional network that coordinates this event.  
 
Thrombocytopenia represents a major dose-limiting toxicity of certain drugs that block PPF 
by targeting the Rho/Rac/CDC42 cascade, including bortezomib and histone deacetylase 
inhibitors [29-31]. Modulation of this pathway leads to increased levels of phosphorylated 
MLC2, which enhances the motor acivity of non-muscle myosin IIA and inhibits PPF [20, 21]. 
In this study, we show that incubation of megakaryocytes with anagrelide results in MLC2 
phosphorylation, which may represent a plausible explanation for the observed block in 
thrombopoiesis.  The partial reversion of anagrelide-induced reduction in PPF achieved after 
inhibiting myosin II activity with blebbistation further supports this possibility. In contrast, the 
fact that myosin pathway blockade was not able to counteract the repressive effect of 
anagrelide on megakaryocyte maturation, as assessed by CD42b expression, indicates that 
additional mechanisms may be responsible for anagrelide´s effects on megakaryopoiesis. 
In conclusion, this work shows that anagrelide reduces platelet counts by targeting two 
sequential steps of platelet production, including megakaryocyte maturation and PPF from 
mature megakaryocytes. Whereas the block in thrombopoiesis may be ascribed to 
modulation of signals controlling myosin II activity, this pathway seems not to be involved on 
anagrelide´s effect on megakaryocyte maturation, suggesting that more than a single 
molecular mechanism may be responsible for anagrelide platelet-lowering activity. Further 
work on the mechanisms underlying the effects of anagrelide on the megakaryocyte may 
contribute to our knowledge of the pathways regulating platelet biogenesis.  
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Figure legends 
Figure 1. Anagrelide inhibits proplatelet formation.  A) Dose-dependent effect of anagrelide 
(ANA) on PPF. At day 13 of culture, megakaryocytes were harvested, replated in fresh 
medium and treated with increasing concentrations of anagrelide. The percentage of 
proplatelet-forming megakaryocytes grown in suspension cultures was monitored by phase-
contrast microscopy.  A dose-dependent reduction in proplatelet formation was found. 
Results represent mean±SEM, n=2 independent experiments.  B) Inhibition in PPF induced 
by 50ηM anagrelide. A significant decrease in thrombopoiesis compared to control cells is 
shown, n= 6 independent experiments, *** P < 0.001, paired t-test  C) Representative 
images of control (left panel) and 50ηM anagrelide-treated (right panel) cultures, showing 
fewer proplatelet-bearing megakaryocytes in the latter. Arrows indicate proplatelets. Insets 
show a magnified view of proplatelets in control and anagrelide-treated cutures. D) Time 
course effect of 50ηM anagrelide on proplatelet formation. Megakaryocytes were treated 
with 50ηM anagrelide during increasing periods of time, showing that the degree of inhibition 
in PPF increases over time. Data represent mean±SEM, n=3. ** P < 0.01, **P < 0.001, 
repeated measures ANOVA. 
 
Figure 2. A) Decrease in proplatelet complexity in megakaryocytes treated with anagrelide. 
Cord blood-derived day 13 megakaryocytes were treated with 50ηM anagrelide (ANA) and 
plated on fibrinogen matrices. After 48-hour incubation, megakaryocytes were fixed, stained 
with FITC-conjugated CD61 antibody and Hoescht and proplatelets were analyzed by 
fluorescence microscopy. Panel A shows control cord blood-derived proplatelet-bearing 
megakaryocytes and panel B illustrates proplatelets in cells exposed to anagrelide, showing 
decreased overall complexity. B) The effect of anagrelide on proplatelet architecture was 
analyzed using an image analysis software. Results show a trend towards reduced number 
of tips, a decrease in the number of swellings for each proplatelet-bearing megakaryocyte, a 
reduction in proplatelet length and increased maximum shaft width in megakaryocytes 
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paired t-test.   C) Effect of anagrelide on proplatelet formation from primary megakaryocyte 
culture derived from peripheral blood CD34+ cells from a patient with essential 
thrombocythemia. Megakaryocytes were grown in suspension and exposed to 50ηM 
anagrelide after reaching maturation and proplatelet formation was monitored by phase-
contrast microscopy. Representative image showing proplatelets with extensive ramification 
in untreated culture is depicted in the left panel, whereas only rudimentary proplatelets are 
seen after incubation with anagrelide (right panel).  
 
Figure 3. A) Effect of anagrelide on VASP phosphorylation. Cells were exposed to 
anagrelide (ANA) as detailed below, then cell lysates were immunoblotted using anti- 
phospho (p)-VASP (Ser157) antibody and membranes were reprobed with anti-β-actin 
antibody. Treatment of megakaryocytes (MKs) with 500ηM anagrelide since day 1 to day 12 
of culture (schedule A, as detailed in Materials and Methods) (left lanes), induced VASP 
phosphorylation, while no change in p-VASP was evident after addition of 50ηM anagrelide 
to mature day 13 megakaryocytes during a 48-hour period in schedule B (right lanes). 
Incubation of platelets with 100µM dibutyryl (db)-cAMP is shown as a positive control for 
VASP phosphorylation. Relative optical density (OD) between pVASP and β-actin is 
depicted in the lower panel. B) Effect of increasing concentrations of db-cAMP compared to 
500ηM anagrelide on megakaryocyte p-VASP levels. Densitometric analysis of reactive 
bands illustrating p-VASP/β-actin ratio is shown on the bar graph.  
 
Figure 4. (A) Effect of protein kinase A inhibitor, PKI, and competitive inhibitor Rp-cAMP on 
anagrelide-induced inhibition in megakaryocyte maturation. Preincubation with 100ηM PKI or 
500µM Rp-cAMP failed to revert the inhibitory effect of 500ηM anagrelide (ANA) added 
since day 1 to day 12 (treatment schedule A, as detailed in Material and Methods) on the 
percentage of CD41+CD42b+ cells, n=3 independent experiments, ** P < 0.01, ***P < 0.001 
vs. untreated control, †† and ## P < 0.01 vs. PKI and Rp-cAMP, respectively, repeated 
measures ANOVA. (B) Effect of PKI and Rp-cAMP on anagrelide-induced inhibition in 
thrombopoiesis. As shown, incubation of cells with both pharmacologic inhibitors prior to cell 
exposure to 50ηM anagrelide from day 13 to day 15 under schedule B was not able to 
counteract the block in proplatelet formation, n=3 independent experiments, ** P < 0.01 vs. 
untreated control, †† P < 0.01 vs. PKI and # P < 0.05 vs. Rp-cAMP, respectively, repeated 
measures ANOVA. (C) Reversal of 20µM dibutyryl (db)-cAMP-induced inhibition in 
proplatelet formation by pretreatment with 100ηM PKI PKI, n=3 independent experiments, ** 
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Figure 5. Gene expression levels of molecules involved in proplatelet formation in mature 
megakaryocytes incubated with anagrelide. Megakaryocytes were differentiated from cord 
blood CD34+ cells, then CD41+ cells were purified by fluorescence activated cell sorting at 
day 9 and exposed to 50ηM anagrelide (ANA) at day 13 during 48 hours, after which mRNA 
levels of selected genes were measured by qPCR and normalized to GAPDH. Error bars 
represent mean ±SD of triplicate. 
 
Figure 6. A) Myosin light chain phosphorylation status in anagrelide-treated 
megakaryocytes. Mature day 13 megakaryocytes were exposed to 50ηM anagrelide (ANA) 
during 48hs, lysed and immunoblotted with phospho-myosin light chain (MLC) 2 (Ser19) 
antibody. Membranes were reprobed with β-actin. pMLC2 phosphorylation is shown in cells 
treated with anagrelide, while exposure to 20µM dibutyryl (db)-cAMP failed to induce MLC2 
phosphorylation. B) Effect of blebbistatin on anagrelide-induced inhibition in thrombopoiesis. 
Mature day 13 megakaryocytes were incubated with increasing concentrations of 
blebbistatin during 30min., then exposed to 50ηM anagrelide and proplatelet formation was 
monitored by phase-contrast microcopy. Blebbistatin induced a dose-dependent increase in 
proplatelet counts in control cultures and in cells incubated with anagrelide, and partially 
reverted anagrelide-induced inhibition in proplatelet formation, n=3 independent 
experiments, * P < 0.05 ** P < 0.01 *** P < 0.001 vs control, ††† P <0.001 vs the 
corresponding concentration of blebbistatin for each condition (e.g. 25µM, 50µM and 100µM 
blebbistatin, respectively), repeated measures ANOVA.  
 
Figure 7. Effect of blebbistatin on anagrelide-induced inhibition in megakaryopoiesis. Day 7 
megakaryocytes were incubated with 20µM blebbistatin during 30 min. followed by treatment 
with 500ηM anagrelide (ANA). On day 10, megakaryocyte nuclear lobulation and size were 
assessed by immunofluorescence analysis and CD42b mean fluorescence intensity (MFI) 
was measured by flow cytometry. A) Blebbistatin (Bleb) increased megakaryocyte lobulation, 
as assessed by the percentage of cells classified as stage II and III, in control cells and had 
a partial effect on cells treated with anagrelide, n=5 independent experiments, ** P < 0.01 vs 
untreated, †† P <0.01 vs anagrelide, repeated measures ANOVA. B) Representative image 
of immunofluorescence analysis using CD61-conjugated FITC and Hoescht of untreated 
cells or cells treated from day 7 to day 10 with 500ηM anagrelide, 20µM blebbistatin or 20µM 
blebbistatin followed by 500ηM anagrelide, as indicated. C) Blebbistatin increased 
megakaryocyte size in control cells and, partially, in anagrelide-treated cells, n=5 
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measures ANOVA.  D) Blebbistatin had a mild effect on CD42b expression in control cells 
but not in cells treated with anagrelide, failing to revert anagrelide-induced reduction in 
CD42b levels. n=4 independent experiments, **P < 0.01, *** P < 0.001 vs. untreated control, 




Supplementary Figure 1. A. Ploidy analysis of megakaryocytes treated with anagrelide. 
Cells were grown in the absence of anagrelide, then day 13 megakaryocytes were incubated 
with 50ηM anagrelide during 48 hours and ploidy was measured in the CD61+ population by 
flow cytometry after permeabilization with 0.1% Tween, and incubation with 100 μg/mL 
propidium iodide and 100μg/mL RNAse. Mean ploidy was calculated by taking into account 
number of cells in each ploidy class relative to total number of cells and was 2.4N for control 
cells and 2.6N for anagrelide-treated cells. B. Analysis of megakaryocyte maturation stages 
after immunofluorescence staining showed no significant difference between treated and 
control cells, n= 4 independent experiments.    
 
Supplementary Figure 2. Partial reversal of anagrelide-induced inhibition in platelet 
aggregation by preincubation with PKI. Platelet-rich-plasma from a healthy individual was 
prepared by centrifugation at 200g during 10 min. and adjusted to 300 x 109/L. Platelets 
were incubated with 10µM PKI or vehicle during 10 min. at 37ºC, then exposed to 1µM 
anagrelide or vehicle at 37ºC during 10 min. and stimulated with 2µM ADP (Biopool, Bray, 
Ireland). Aggregation was evaluated using a lumi-aggregometer (Chrono Log Corp, 
Havertown, PA, USA) and results were expressed as percentage of maximal light 
transmission. Aggregation traces of platelets incubated with vehicle, anagrelide alone and 
PKI followed by anagrelide and then stimulated with ADP are shown.  
Supplementary Figure 3. Myosin light chain phoshorylation after adhesion to type I 
collagen. Day 13 megakaryocytes were treated or not with 50ηM anagrelide and allowed to 
adhere to plates coated with 25μg/mL type I collagen during 16 hours. After removal of non-
adherent cells, adherent cells were lysed and pMLC2 levels were assessed by western blot, 
showing similar phosphorylation levels in both control and anagrelide-treated 
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